|
 |
en espaņol
Guidelines
for Naming Measles Strains or Sequences
The
strain names will provide information that is essential for interpretation
of the molecular data. Since sequence data may be derived from viruses
isolated in cell culture or from RNA extracted directly from clinical
material, strains or sequences will be designated as either
|
(1) |
MVi:
measles virus isolate in cell culture; or |
|
(2) |
MVs:
measles virus sequence derived from RNA extracted
from clinical material. |
Other information to be included in the strain/sequence name:
|
-
|
city/province
where case of measles was diagnosed, write full name or abbreviation
(required); |
|
-
|
country,
use WHO 3-letter (exit site) designation
(required); |
|
-
|
date
of specimen collection by epidemic week (1-52)
and year (required); |
|
-
|
isolate
number if more than 1 per week in the same location (optional); |
|
-
|
genotype
(optional initially, required after sequencing
of at least 450 nucleotides of the
N gene  (text-only) is
completed); |
|
-
|
special
designation for sequences derived from measles
inclusion body encephalitis (MIBE) or subacute
sclerosing panencephalitis (SSPE) cases (optional). |
The
following examples illustrate the proposed nomenclature:
MVi/NewYork.USA/03.98/2 [D2]
MVs/London.UNK/17.97 [G3] SSPE
|
 |
|
|
|
|
